- Johnson & Johnson will acquire Halda Therapeutics for $3.05 billion in cash.
- The transaction is expected to close within the next few months, pending antitrust clearance.
- Halda's lead candidate, HLD-0915, targets prostate cancer, with diagnoses projected to reach 1.7 million globally by 2030.
- Johnson & Johnson anticipates a $0.15 EPS dilution in 2026 due to the acquisition.
Acquisition Details
Johnson & Johnson has announced a definitive agreement to acquire Halda Therapeutics for $3.05 billion in cash. The transaction is expected to close within the next few months, subject to antitrust clearance and other customary closing conditions.
Halda's Lead Candidate
Halda's lead candidate, HLD-0915, is a clinical-stage therapy for prostate cancer. New diagnoses of prostate cancer are projected to reach 1.7 million globally by 2030. HLD-0915 offers a novel precision cancer cell-killing approach that can overcome resistance to treatment.
Pipeline and Platform
The acquisition includes Halda's proprietary Regulated Induced Proximity Targeting Chimera (RIPTACâ„¢) platform, which develops oral, targeted therapies for multiple types of solid tumors. The platform may also enable the creation of novel targeted therapies beyond oncology.
Financial Impact
Johnson & Johnson expects a $0.15 dilution in Adjusted Earnings Per Share (EPS) in 2026 due to short-term financing and a non-recurring charge related to equity awards for Halda employees upon closing.
